Purpose of Review <p>Male fertility evaluation is increasingly shifting outside traditional clinics as direct-to-consumer (DTC) semen testing and cryopreservation services expand. This review synthesizes current evidence on the accuracy, clinical utility, and cost implications of DTC products and evaluates their role alongside guideline-based care.</p> Recent Findings <p>Smartphone-based platforms and other DTC products show strong performance for screening sperm concentration and motility, and mail-in cryopreservation allows access to laboratory analysis from home. However, most DTC tests do not replicate the diagnostic scope of clinical semen analysis and often require confirmatory evaluation. Costs vary widely across platforms, with inconsistent transparency and hidden fees noted in both DTC and traditional models. Early evidence also shows that DTC services disproportionately serve affluent users, despite potential to improve access for underserved populations.</p> Summary <p>DTC semen analysis and cryopreservation can enhance convenience and early engagement but should complement rather than replace standard evaluation. Their utility depends on clinical context and cost-to-value considerations. We outline principles to guide clinicians in integrating DTC results into counseling and care while addressing issues of equity, transparency, and appropriate follow-up.</p>